Chimeric antigen receptor T cell therapy-associated cytokine release syndrome research hub

A phase I/II, single arm, open label study of dasatinib as toxicity prophylaxis in the context of therapy with idecabtagene vicleucel in relapsed/refractory multiple myeloma

This study looks at a medicine called dasatinib (Sprycel) to see if it can help prevent or reduce side effects when people with a type of blood cancer called multiple myeloma are treated with a special cell therapy called ide-cel (Abecma).